fresenius medical care ag - FMS

FMS

Close Chg Chg %
25.03 0.57 2.26%

Closed Market

25.60

+0.57 (2.26%)

Volume: 1.15M

Last Updated:

May 2, 2025, 3:59 PM EDT

Company Overview: fresenius medical care ag - FMS

FMS Key Data

Open

$25.75

Day Range

25.57 - 26.04

52 Week Range

17.93 - 26.04

Market Cap

$14.68B

Shares Outstanding

586.83M

Public Float

586.39M

Beta

0.84

Rev. Per Employee

N/A

P/E Ratio

25.23

EPS

$0.99

Yield

177.17%

Dividend

$0.44

EX-DIVIDEND DATE

May 17, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

464.72K

 

FMS Performance

1 Week
 
4.62%
 
1 Month
 
6.94%
 
3 Months
 
5.09%
 
1 Year
 
22.03%
 
5 Years
 
-33.43%
 

FMS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About fresenius medical care ag - FMS

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

FMS At a Glance

Fresenius Medical Care AG
Else-Kröner-Strasse 1
Bad Homburg, Hessen 61352
Phone 49-6172-609-0 Revenue 20.92B
Industry Medical/Nursing Services Net Income 581.86M
Sector Health Services Employees 113,840
Fiscal Year-end 12 / 2025
View SEC Filings

FMS Valuation

P/E Current 25.234
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 22.834
Price to Sales Ratio 0.635
Price to Book Ratio 0.88
Price to Cash Flow Ratio 5.147
Enterprise Value to EBITDA 7.127
Enterprise Value to Sales 1.172
Total Debt to Enterprise Value 0.464

FMS Efficiency

Revenue/Employee 183,744.416
Income Per Employee 5,111.169
Receivables Turnover 5.298
Total Asset Turnover 0.579

FMS Liquidity

Current Ratio 1.381
Quick Ratio 0.993
Cash Ratio 0.235

FMS Profitability

Gross Margin 24.634
Operating Margin 8.502
Pretax Margin 4.768
Net Margin 2.782
Return on Assets 1.611
Return on Equity 3.861
Return on Total Capital 2.199
Return on Invested Capital 2.245

FMS Capital Structure

Total Debt to Total Equity 75.319
Total Debt to Total Capital 42.961
Total Debt to Total Assets 32.708
Long-Term Debt to Equity 66.961
Long-Term Debt to Total Capital 38.194
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fresenius Medical Care Ag - FMS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
20.82B 20.38B 21.03B 20.92B
Sales Growth
+2.26% -2.12% +3.18% -0.55%
Cost of Goods Sold (COGS) incl D&A
14.82B 14.80B 15.70B 15.76B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.87B 1.81B 1.74B 1.66B
Depreciation
1.69B 1.63B 1.58B 1.51B
Amortization of Intangibles
180.05M 177.63M 164.69M 148.39M
COGS Growth
+5.56% -0.14% +6.04% +0.42%
Gross Income
6.00B 5.58B 5.33B 5.15B
Gross Income Growth
-5.07% -7.00% -4.42% -3.39%
Gross Profit Margin
+28.81% +27.38% +25.36% +24.63%
2021 2022 2023 2024 5-year trend
SG&A Expense
3.64B 3.74B 3.62B 3.37B
Research & Development
260.96M 240.28M 250.79M 198.48M
Other SG&A
3.38B 3.50B 3.37B 3.18B
SGA Growth
-4.29% +2.72% -3.20% -6.72%
Other Operating Expense
- - - -
-
Unusual Expense
247.67M 444.27M 318.27M 527.05M
EBIT after Unusual Expense
2.11B 1.40B 1.40B 1.25B
Non Operating Income/Expense
50.79M 177.60M 30.54M 175.58M
Non-Operating Interest Income
85.06M 69.69M 93.95M 76.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
416.20M 364.84M 443.14M 429.50M
Interest Expense Growth
-10.11% -12.34% +21.46% -3.08%
Gross Interest Expense
421.13M 367.19M 445.84M 431.82M
Interest Capitalized
4.93M 2.35M 2.70M 2.32M
Pretax Income
1.75B 1.21B 985.14M 997.37M
Pretax Income Growth
-16.70% -30.73% -18.68% +1.24%
Pretax Margin
+8.40% +5.94% +4.68% +4.77%
Income Tax
417.04M 341.52M 324.94M 341.87M
Income Tax - Current - Domestic
(13.80M) (5.70M) 22.65M 75.69M
Income Tax - Current - Foreign
351.34M 390.80M 434.35M 344.80M
Income Tax - Deferred - Domestic
21.75M 17.83M 36.78M (40.85M)
Income Tax - Deferred - Foreign
57.75M (61.41M) (168.83M) (37.76M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.44B 939.91M 791.87M 801.39M
Minority Interest Expense
295.16M 232.18M 252.40M 219.54M
Net Income
1.15B 707.73M 539.47M 581.86M
Net Income Growth
-13.69% -38.23% -23.77% +7.86%
Net Margin Growth
+5.50% +3.47% +2.56% +2.78%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.15B 707.73M 539.47M 581.86M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.15B 707.73M 539.47M 581.86M
EPS (Basic)
1.9555 1.2067 0.9193 0.9915
EPS (Basic) Growth
-13.36% -38.29% -23.82% +7.85%
Basic Shares Outstanding
585.89M 586.49M 586.83M 586.83M
EPS (Diluted)
1.9547 1.2067 0.9193 0.9915
EPS (Diluted) Growth
-13.33% -38.27% -23.82% +7.85%
Diluted Shares Outstanding
586.13M 586.49M 586.83M 586.83M
EBITDA
4.24B 3.65B 3.46B 3.44B
EBITDA Growth
-2.13% -13.81% -5.24% -0.59%
EBITDA Margin
+20.34% +17.91% +16.45% +16.44%

Snapshot

Average Recommendation HOLD Average Target Price 26.233
Number of Ratings 22 Current Quarters Estimate 0.513
FY Report Date 06 / 2025 Current Year's Estimate 2.045
Last Quarter’s Earnings 0.425 Median PE on CY Estimate N/A
Year Ago Earnings 1.632 Next Fiscal Year Estimate 2.30
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 18 18
Mean Estimate 0.51 0.56 2.05 2.30
High Estimates 0.57 0.63 2.43 2.67
Low Estimate 0.47 0.53 1.78 1.84
Coefficient of Variance 8.50 7.98 7.33 8.66

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 8
OVERWEIGHT 1 1 1
HOLD 9 9 9
UNDERWEIGHT 2 2 1
SELL 3 3 3
MEAN Hold Hold Hold

Fresenius Medical Care Ag in the News